Section 361 HCT/P FDA Compliance Requirements for Biologics

Section 361 HCT/P FDA compliance requirements for biologics demand that human cells, tissues, and cellular and tissue-based products be minimally manipulated, intended solely for homologous use, and processed without systemic or metabolic dependence on living cells for non-autologous applications. Governed by 21 CFR Part 1271, licensed practices utilizing allogeneic human tissue must maintain precise chain-of-custody logs, verify supplier registration, and align clinical claims with regulatory boundaries. Adherence to these standards protects clinical practices from regulatory enforcement actions and ensures patient safety across all regenerative procedures.

Understanding 21 CFR Part 1271 and Section 361 Criteria

Under Title 21 of the Code of Federal Regulations (CFR) Part 1271, the U.S. Food and Drug Administration (FDA) establishes a risk-based framework for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Products regulated under Section 361 of the Public Health Service (PHS) Act are subject to registration, donor screening, testing, and Current Good Tissue Practice (cGTP) requirements, but do not require pre-market approval or pre-market clearance if they satisfy four strict criteria:

1. Minimal Manipulation: Processing does not alter the original relevant characteristics of structural tissue (e.g., amniotic membrane, Wharton's jelly, skin, umbilical cord tissue) related to its utility for reconstruction, repair, or replacement, or alter the relevant biological characteristics of non-structural tissue.
2. Homologous Use: The tissue is intended to perform the same basic function in the recipient as it performed in the donor (e.g., providing structural support, coverage, or cushioning).
3. No Combination with Other Agents: The product is not combined with another drug, device, or biological agent, except for water, crystalloids, or sterilizing/preserving agents that do not raise new safety concerns.
4. Metabolic and Systemic Effect Limits: Either the product does not rely on the metabolic activity of living cells for its primary function, or it is limited to autologous use, allogeneic use between first- or second-degree blood relatives, or reproductive use.

If an HCT/P fails to meet any single criterion listed above, it falls under Section 351 of the PHS Act. Section 351 products are classified as biological drugs, requiring an Investigational New Drug (IND) application and an approved Biologics License Application (BLA) before distribution or clinical administration.

Minimal Manipulation vs. Homologous Use: Clinical and Operational Perspectives

Navigating compliance requires coordination between clinical leaders establishing patient protocols and operational managers overseeing vendor procurement and clinical administration.

Clinical Perspective: Aligning Indications with Homologous Function

For clinicians, Section 361 compliance directly dictates clinical documentation, informed consent, and treatment protocols. When selecting biologics for clinical procedures, physicians must ensure that the treatment rationale centers on structural supplementation rather than systemic cellular signaling or unapproved therapeutic disease claims.

• Structural Tissue Applications: Allogeneic umbilical cord matrices, Wharton’s jelly, and amniotic tissues are compliant under Section 361 when applied to serve as a physical matrix, cushion, or biological barrier for damaged structural tissue.
• Claim Boundaries: Clinicians must avoid advertising or documenting non-homologous uses, such as treating systemic neurodegenerative disorders, autoimmune conditions, or organ failure using Section 361 allografts, as these claims trigger Section 351 drug status.

Operational Perspective: Procurement, Tracking, and Vendor Oversight

For practice managers, compliance is an operational discipline focused on vendor auditing, lot tracking, and risk mitigation. Practice administrators must establish standardized operating procedures (SOPs) that protect the practice during regulatory reviews.

• FDA Establishment Registration: Ensure that every vendor supplying tissue-derived products holds an active FDA Tissue Establishment Registration (Form FDA 3356) and adheres to cGTP standards.
• Chain-of-Custody Tracking: Track every biological unit from delivery through storage to clinical administration. Storage refrigeration and freezer units must feature continuous temperature logging to maintain tissue integrity.
• Certificate of Analysis (CoA) Archiving: Maintain accessible archives of CoAs and donor screening eligibility documentation for every lot number received.

FDA Compliance Checklist for Practice Procurement

Practice administrators evaluating prospective suppliers of human tissue products should execute a thorough compliance checklist prior to issuing purchase orders:

• FDA Form 3356 Verification: Confirm the manufacturer and distributor hold an active FDA Tissue Establishment Registration.
• cGTP Quality Documentation: Verify the supplier conducts donor screening for communicable diseases (including HIV, Hepatitis B, Hepatitis C, Syphilis, and HTLV) in accordance with 21 CFR 1271 Subpart C.
• Minimal Manipulation Validation: Ensure the supplier provides documentation demonstrating that processing methods (e.g., micronization, cryopreservation) do not alter the native structural characteristics of the tissue.
• Homologous Use Product Labeling: Inspect product package inserts to confirm that indications and instructions strictly adhere to structural tissue repair or replacement.
• Lot-Specific Certificates of Analysis: Confirm that each shipment includes a complete CoA detailing sterility testing, endotoxin screening, and tissue verification.
• Cold Chain Verification: Validate that shipments arrive with temperature monitoring indicators to confirm storage specifications were maintained throughout transit.

Operational Risk Management and Documentation Protocols

Operating a compliant practice requires maintaining clear separation between compliant Section 361 structural tissue products and regulated devices or systemic compounds. Practice management should establish explicit administrative protocols across clinical specialties, whether serving regenerative medicine doctors or multidisciplinary surgical centers.

Record Retention

FDA guidelines require tissue facilities and receiving entities to maintain donor eligibility records and administration logs for a minimum of 10 years beyond the date of administration or expiration. Practice management software should incorporate mandatory fields for biologic lot numbers, donor identification codes, expiration dates, and receiving patient record IDs.

Vendor Evaluation Protocols

Work exclusively with established medical distributors who maintain clear regulatory transparency. Avoid suppliers who promote allogeneic live cell suspensions, stem cell injections, or high-potency systemic claims under Section 361 exemptions, as these products expose practices to severe compliance liabilities.

What This Means for Your Practice

Maintaining strict Section 361 HCT/P compliance protects your organization's reputation, operational stability, and legal integrity while delivering safe clinical care.

• Audit Existing Inventory: Review all human tissue products currently stocked in your clinical inventory to verify active supplier FDA registration and complete donor screening documentation.
• Update Clinical Marketing Materials: Audit practice websites, patient brochures, and digital channels to eliminate non-homologous claims or therapeutic language that implies drug-level systemic cures.
• Standardize Procurement SOPs: Establish a clear policy requiring vendor compliance documentation, temperature log reviews, and lot tracking entry before any biologic product is cleared for clinical use.
• Train Clinical and Administrative Staff: Conduct annual staff reviews covering 21 CFR 1271 handling, proper storage procedures, and complete chain-of-custody documentation.

To review compliant biological supplies, learn more about our distribution standards on our about page, or contact our team to discuss procurement protocols tailored to your clinical operations.

For custom operational reviews or compliance verification guidance when integrating biologics into your facility, contact the team at Dallas Regenerative Solutions today.